›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:Oncotype MAP™ Pan-Cancer Tissue Test
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Exact Sciences CorpType:
Laboratory Developed Test
Related tests:
The Oncotype MAP test, previously known as PCDx, is a rapid, comprehensive tumor profiling panel that aids therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer. With minimal tissue requirements, the Oncotype MAP test utilizes next generation sequencing (NGS) and immunohistochemistry (IHC) to provide in-depth insights into genomic alterations in hundreds of cancer-related genes, including tumor mutations, copy number variants, fusions, tumor mutation burden (TMB), microsatellite instability, and protein expression.
Cancer:
Solid Tumor
Gene:
ALK (Anaplastic lymphoma kinase), BRAF (B-raf proto-oncogene), FGFR1 (Fibroblast growth factor receptor 1), FGFR2 (Fibroblast growth factor receptor 2), FGFR3 (Fibroblast growth factor receptor 3), MET (MET proto-oncogene, receptor tyrosine kinase)
See More ...
ALK (Anaplastic lymphoma kinase), BRAF (B-raf proto-oncogene), FGFR1 (Fibroblast growth factor receptor 1), FGFR2 (Fibroblast growth factor receptor 2), FGFR3 (Fibroblast growth factor receptor 3), MET (MET proto-oncogene, receptor tyrosine kinase), MSI (Microsatellite instability), NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1), NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2), NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3), RET (Ret Proto-Oncogene), ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS), TMB (Tumor Mutational Burden)
Method:
Next-Generation Sequencing (NGS) / Immunohistochemistry (IHC)
